* Report out on 7 November * Q3e sales of EUR 40m (44m), EBIT EUR 2.
The analysis of the data that has now been collected will be a major trigger.
* Report out on 4 November * Q3e sales of SEK 225m (+12% y-o-y), EBIT adj.
Redeye gives a short comment on Gapwaves fully guaranteed rights issue of approximately SEK78m and a...
Before Taaleri's Q3 2025 results on 28 October, we make slight estimate revisions, reflecting the CM...
Vaisala reports Q3 results on Oct 23. W&E is likely to see its earnings decline in H2 as well, while...
Ahead of Fiskars' Q3 report, we trim our 2025-27 adjusted EBIT estimates by 4-7% and continue to see...
* Report out on 5 November * Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m) * GC&MP the bright spot,...
Atria raised its 2025 guidance today. The company now expects its adjusted EBIT to to be higher in 2...
Omsättningen hålls uppe av en hög aktivitet i Norge, särskilt inom olje- och gasindustrin, medan for...
Redeye provides a short comment on the recent press release announcing that the CADScor® System has ...
* We cut '25e-'27e adj. EBITA by 4-8% * Expect some EBITA growth in Q3 * NTM EV/EBITA ~9x Expectatio...
* Organic growth of 5% offset by FX headwinds * Minor negative revisions on '25e-'27e EBIT * NTM EV/...
Redeye believes gene therapy is an interesting area for imlifidase.
Redeye provides a comment on the Q3 trading update from Cheffelo, released this morning.
